Abstract
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murphy, D., McGown, A., Crowther, D. et al. Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63, 711–714 (1991). https://doi.org/10.1038/bjc.1991.160
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.160
This article is cited by
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Oncogene (2003)
-
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Nature Reviews Cancer (2003)
-
Metallothionein in Pancreatic Endocrine Neoplasms
Modern Pathology (2000)